Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a type of blood cancer called a T-cell malignancy where the cancer cells carry a protein called CD7, and whose cancer has come back or stopped responding to treatment, having already tried all standard options (such as chemotherapy or stem cell transplant)
- People whose cancer has been confirmed to carry the CD7 protein through specialised laboratory testing of bone marrow, spinal fluid, or tumour tissue samples
- People aged between 1 and 70 years old, either male or female
- People with no history of severe allergic reactions
- People who are reasonably well and able to carry out daily activities, as measured by a standard medical scoring system (a score of 0–2 on the ECOG scale — confirm with trial site if unsure what this means)
- People who are expected to live for at least 60 days, as assessed by the treating doctor
- People who are able to give signed consent before any trial procedures begin; for children aged 1–7, a legal guardian must sign consent; for those aged 8–18, both the young person and a legal guardian must sign; adults aged 19–70 must be able to sign consent themselves
Who may not be able to join:
- People with raised pressure in the brain or who are unconscious
- People with acute heart failure or a serious irregular heartbeat
- People with acute respiratory (breathing) failure
- People who have another type of cancer in addition to their T-cell malignancy
- People with a condition where blood clots form abnormally throughout the body (called diffuse intravascular coagulation)
- People whose kidney function markers (creatinine and/or blood urea nitrogen) are more than 1.5 times higher than the normal range
- People with blood poisoning (sepsis) or any other infection that is not under control
- People with diabetes that is not well controlled
- People with a serious psychological or psychiatric condition
- People who have noticeable lesions or abnormalities in the brain shown on an MRI scan
- People with a known tendency toward allergic reactions
- People who have received an organ transplant
- People who are pregnant or breastfeeding
- People who have an active, uncontrolled infection including hepatitis B, hepatitis C, HIV, or syphilis
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 86+18611422920
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose-Limiting Toxicity (DLT) in phase I; Overall Response Rate (ORR) in phase II
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.